Feasibility of prolonged use of interferon‐α in metastatic kidney carcinoma

Kankuri, Minna; Pelliniemi, Tarja‐Terttu; Pyrhönen, Seppo; Nikkanen, V.; Helenius, Hans; Salminen, Eeva

doi:10.1002/1097-0142(20010815)92:4<761::aid-cncr1380>3.0.co;2-#

Cited by 30 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone metastasis has been identified as an independent prognostic variable associated with poor survival in patients with metastatic RCC [5]. In their skeletal history, the majority of these patients may experience extremely debilitating skeletal complications (i.e.…”

Section: Discussionmentioning

confidence: 99%

“…Traditional cytokines or immunotherapy (interferon alfa or interleukin-2) might have been used for some patients in our retrospective analysis, but are not very effective in treating metastatic bone disease [5]. In the past 6 years, widespread use of targeted therapies directed at the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) signaling pathways [18], [19] has greatly changed the clinical management of metastatic RCC.…”

Section: Discussionmentioning

confidence: 99%

“…Bone metastasis has been identified as an independent prognostic variable associated with poor survival in patients with metastatic RCC [5]. With disease progression, approximately 30% of RCC patients develop bone metastasis [6], representing the second most common site of distant metastatic spread (after lung) in advanced RCC.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

et al. 2013

View full text Add to dashboard Cite

BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P<0.05).ConclusionsRCC patients with bone metastasis are at continuous risk of SREs, and in this survey ZOL effectively reduced this risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

et al. 2013

View full text Add to dashboard Cite

show abstract

“…For localized RCC, nephrectomy is the only curative treatment (Robson et al 2002), and currently there is no adjuvant therapy in RCC. Possible treatments for mRCC, in addition to cytoreductive nephrectomy (Flanigan et al 2001, Mickisch et al 2001, are immunomodulators, such as interferon- (IFN-) (Kankuri et al 2001, Pyrhönen et al 1999, interleukin-2 (IL-2) (Négrier et al 2007), and more recently tyrosine kinase inhibitors, such as sunitinib (Motzer et al 2007), sorafenib (Escudier et al 2007), and mTOR inhibitor temsirolimus (Hudes et al 2007). Everolimus, another mTOR inhibitor, has an encouraging antitumor activity against mRCC .…”

Section: Wwwintechopencommentioning

confidence: 99%

“…Additionally, vaccine therapy in RCC is being studied (Rini et al 2011). The stabilization of the disease has been shown to be beneficial for the survival of mRCC patients (Thiam et al 2010, Kankuri et al 2001). …”

Section: Wwwintechopencommentioning

confidence: 99%

Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions

Kankuri-Tammilehto¹

2012

Emerging Research and Treatments in Renal Cell Carcinoma

View full text Add to dashboard Cite

Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma

Lipton

Zheng

Seaman

2003

Cancer

210

171

View full text Add to dashboard Cite

BACKGROUND The objective of this study was to assess the efficacy and safety of zoledronic acid in patients with bone metastases secondary to renal cell carcinoma (RCC). METHODS A retrospective subset analysis of patients with RCC enrolled in a multicenter, randomized, placebo‐controlled study of zoledronic acid was performed. Patients were randomized to receive zoledronic acid (4 or 8 mg as a 15‐minute infusion) or placebo with concomitant antineoplastic therapy every 3 weeks for 9 months. The primary efficacy analysis was the proportion of patients with one or more skeletal‐related events (SREs), which were defined as pathologic fracture, spinal cord compression, radiation therapy, or surgery to bone. Secondary analyses included time to first SRE, skeletal morbidity rate (events per year), disease progression, and multiple event analysis. RESULTS In this subset of 74 patients with RCC, zoledronic acid (4 mg) was found to significantly reduce the proportion of patients with an SRE (37% vs. 74% for placebo; P = 0.015). Similarly, zoledronic acid significantly reduced the mean skeletal morbidity rate (2.68 vs. 3.38 for placebo; P = 0.014) and extended the time to the first event (median not reached vs. 72 days for placebo; P = 0.006). A multiple event analysis demonstrated that the risk of developing an SRE was reduced by 61% compared with placebo (hazard ratio of 0.394; P = 0.008). The median time to progression of bone lesions was significantly longer for patients who were treated with zoledronic acid (P = 0.014 vs. placebo). Zoledronic acid appeared to be well tolerated; the most common adverse events in all treatment groups included bone pain, nausea, anemia, and emesis. CONCLUSIONS Zoledronic acid (4 mg as a 15‐minute infusion) demonstrated significant clinical benefit in patients with bone metastases from RCC, suggesting that further investigation of zoledronic acid in this patient population is warranted. Cancer 2003;98:962–9. © 2003 American Cancer Society. DOI 10.1002/cncr.11571

show abstract

Feasibility of prolonged use of interferon‐α in metastatic kidney carcinoma

Cited by 30 publications

References 28 publications

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions

Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma

Contact Info

Product

Resources

About